Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
56
DMAC Quote, Financials, Valuation and Earnings
Last price:
$8.42
Seasonality move
:
9.66%
Day range:
$8.10 - $8.49
52-week range:
$3.19 - $10.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.49x
Volume:
180.6K
Avg. volume:
211.6K
1-year change:
27.38%
Market cap:
$438.5M
Revenue:
--
EPS (TTM):
-$0.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
-- | -$0.18 | -- | -7.47% | $15.50 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.5M | $0.14 | 13.44% | 28.72% | $31.21 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
AVTR
Avantor, Inc.
|
$1.6B | $0.22 | -2.36% | 66.15% | $11.04 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
|
XOMA
XOMA Royalty Corp.
|
$11.1M | -$0.09 | 27.73% | -80.01% | $64.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
$8.42 | $15.50 | $438.5M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$23.99 | $31.21 | $4.1B | 15.44x | $0.00 | 0% | 3.86x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$336.19 | $457.00 | $44.6B | 148.95x | $0.00 | 0% | 12.08x |
|
AVTR
Avantor, Inc.
|
$9.03 | $11.04 | $6.2B | 10.97x | $0.00 | 0% | 0.94x |
|
SVRA
Savara, Inc.
|
$5.53 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
|
XOMA
XOMA Royalty Corp.
|
$25.81 | $64.50 | $319.6M | 34.62x | $0.54 | 0% | 8.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
0.51% | 2.599 | 0.07% | 10.50x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.900 | 1.52% | 2.70x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
AVTR
Avantor, Inc.
|
42.61% | 1.095 | 52.87% | 1.07x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
|
XOMA
XOMA Royalty Corp.
|
54.99% | 1.628 | 26.95% | 3.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
-$18K | -$9M | -78.63% | -79.25% | -- | -$6.6M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
AVTR
Avantor, Inc.
|
$448.3M | $136M | -5.3% | -8.99% | 8.18% | $117.2M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
|
XOMA
XOMA Royalty Corp.
|
$8.5M | -$1.3M | 7.44% | 17.31% | -14.22% | -$957K |
DiaMedica Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DMAC or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of 25.76%. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About DMAC or ACAD?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 84.09%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.21 which suggests that it could grow by 30.1%. Given that DiaMedica Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe DiaMedica Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is DMAC or ACAD More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.106, which suggesting that the stock is 10.622% more volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock DMAC or ACAD?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or ACAD?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 3.86x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M ACADACADIA Pharmaceuticals, Inc.3.86x 15.44x $278.6M $71.8M
-
Which has Higher Returns DMAC or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of 16.99%. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About DMAC or ALNY?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 84.09%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 35.94%. Given that DiaMedica Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe DiaMedica Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is DMAC or ALNY More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.106, which suggesting that the stock is 10.622% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock DMAC or ALNY?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or ALNY?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 148.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 12.08x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M ALNYAlnylam Pharmaceuticals, Inc.12.08x 148.95x $1.1B $186.4M
-
Which has Higher Returns DMAC or AVTR?
Avantor, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of 3.15%. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Avantor, Inc.'s return on equity of -8.99%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M AVTRAvantor, Inc.26.95% $0.08 $9.7B -
What do Analysts Say About DMAC or AVTR?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 84.09%. On the other hand Avantor, Inc. has an analysts' consensus of $11.04 which suggests that it could grow by 22.21%. Given that DiaMedica Therapeutics, Inc. has higher upside potential than Avantor, Inc., analysts believe DiaMedica Therapeutics, Inc. is more attractive than Avantor, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 AVTRAvantor, Inc.3 14 1 -
Is DMAC or AVTR More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.106, which suggesting that the stock is 10.622% more volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.941, suggesting its less volatile than the S&P 500 by 5.874%.
-
Which is a Better Dividend Stock DMAC or AVTR?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or AVTR?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than Avantor, Inc. quarterly revenues of $1.7B. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than Avantor, Inc.'s net income of $52.4M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 0.94x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M AVTRAvantor, Inc.0.94x 10.97x $1.7B $52.4M
-
Which has Higher Returns DMAC or SVRA?
Savara, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of --. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About DMAC or SVRA?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 84.09%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 95.52%. Given that Savara, Inc. has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe Savara, Inc. is more attractive than DiaMedica Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 SVRASavara, Inc.6 0 0 -
Is DMAC or SVRA More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.106, which suggesting that the stock is 10.622% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock DMAC or SVRA?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or SVRA?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is higher than Savara, Inc.'s net income of -$29.6M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M SVRASavara, Inc.-- -- -- -$29.6M
-
Which has Higher Returns DMAC or XOMA?
XOMA Royalty Corp. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of 52.48%. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat XOMA Royalty Corp.'s return on equity of 17.31%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M XOMAXOMA Royalty Corp.90.59% $0.70 $239.9M -
What do Analysts Say About DMAC or XOMA?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 84.09%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 149.9%. Given that XOMA Royalty Corp. has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than DiaMedica Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 XOMAXOMA Royalty Corp.4 1 0 -
Is DMAC or XOMA More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.106, which suggesting that the stock is 10.622% more volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.461%.
-
Which is a Better Dividend Stock DMAC or XOMA?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios DMAC or XOMA?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 8.98x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M XOMAXOMA Royalty Corp.8.98x 34.62x $9.4M $10.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
